Open Access
Open access
volume 351 issue 9100 pages 417-418

Yttrium-90-labelled somatostatin-analogue for cancer treatment

Andreas Otte 1
J Mueller-Brand 2, 3
S Dellas 2, 3
Eu Nitzsche 2, 3
R Herrmann 2, 3
Hr Maecke 2, 3
1
 
Institute of Nuclear Medicine, Department of Medical Radiology
3
 
and Department of Nuclear Medicine, University Hospital, Freiburg, Germany
Publication typeJournal Article
Publication date1998-02-01
scimago Q1
wos Q1
SJR12.113
CiteScore87.6
Impact factor88.5
ISSN01406736, 1474547X
General Medicine
Found 
Found 

Top-30

Journals

2
4
6
8
10
12
14
16
Seminars in Nuclear Medicine
15 publications, 6.07%
European Journal of Nuclear Medicine and Molecular Imaging
13 publications, 5.26%
International Journal of Cancer
6 publications, 2.43%
Annals of Oncology
5 publications, 2.02%
Recent Results in Cancer Research
5 publications, 2.02%
Nuclear Medicine and Biology
4 publications, 1.62%
Cancer Biotherapy and Radiopharmaceuticals
4 publications, 1.62%
Nuclear Medicine Communications
4 publications, 1.62%
Cancer
4 publications, 1.62%
Clinical Cancer Research
4 publications, 1.62%
Medical radiology
4 publications, 1.62%
Journal of Medicinal Chemistry
3 publications, 1.21%
European Journal of Surgical Oncology
3 publications, 1.21%
Endocrine Reviews
3 publications, 1.21%
Journal of Nuclear Medicine
3 publications, 1.21%
Pharmaceuticals
3 publications, 1.21%
Annals of Nuclear Medicine
3 publications, 1.21%
Syndromes of Hormone Resistance on the Hypothalamic-Pituitary-Thyroid Axis
3 publications, 1.21%
Journal of Clinical Oncology
3 publications, 1.21%
The Lancet
2 publications, 0.81%
Endocrine-Related Cancer
2 publications, 0.81%
Advanced Drug Delivery Reviews
2 publications, 0.81%
Applied Radiation and Isotopes
2 publications, 0.81%
Neuroendocrinology
2 publications, 0.81%
Pharmaceutics
2 publications, 0.81%
Journal of Endocrinological Investigation
2 publications, 0.81%
British Journal of Cancer
2 publications, 0.81%
Endocrinología y Nutrición
2 publications, 0.81%
Best Practice and Research in Clinical Endocrinology and Metabolism
2 publications, 0.81%
2
4
6
8
10
12
14
16

Publishers

10
20
30
40
50
60
70
80
Elsevier
80 publications, 32.39%
Springer Nature
46 publications, 18.62%
Wiley
21 publications, 8.5%
Taylor & Francis
11 publications, 4.45%
American Chemical Society (ACS)
9 publications, 3.64%
MDPI
8 publications, 3.24%
Ovid Technologies (Wolters Kluwer Health)
7 publications, 2.83%
The Endocrine Society
5 publications, 2.02%
Mary Ann Liebert
5 publications, 2.02%
Society of Nuclear Medicine
4 publications, 1.62%
American Association for Cancer Research (AACR)
4 publications, 1.62%
American Society of Clinical Oncology (ASCO)
3 publications, 1.21%
Bioscientifica
2 publications, 0.81%
S. Karger AG
2 publications, 0.81%
Frontiers Media S.A.
2 publications, 0.81%
Royal Society of Chemistry (RSC)
2 publications, 0.81%
Oxford University Press
2 publications, 0.81%
Hindawi Limited
2 publications, 0.81%
Georg Thieme Verlag KG
2 publications, 0.81%
Massachusetts Medical Society
1 publication, 0.4%
Radiological Society of North America (RSNA)
1 publication, 0.4%
SAGE
1 publication, 0.4%
Public Library of Science (PLoS)
1 publication, 0.4%
Jaypee Brothers Medical Publishing
1 publication, 0.4%
Society for Translational Oncology
1 publication, 0.4%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.4%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 0.4%
AME Publishing Company
1 publication, 0.4%
BMJ
1 publication, 0.4%
10
20
30
40
50
60
70
80
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
247
Share
Cite this
GOST |
Cite this
GOST Copy
Otte A. et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment // The Lancet. 1998. Vol. 351. No. 9100. pp. 417-418.
GOST all authors (up to 50) Copy
Otte A., Mueller-Brand J., Dellas S., Nitzsche E., Herrmann R., Maecke H. Yttrium-90-labelled somatostatin-analogue for cancer treatment // The Lancet. 1998. Vol. 351. No. 9100. pp. 417-418.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/S0140-6736(05)78355-0
UR - https://doi.org/10.1016/S0140-6736(05)78355-0
TI - Yttrium-90-labelled somatostatin-analogue for cancer treatment
T2 - The Lancet
AU - Otte, Andreas
AU - Mueller-Brand, J
AU - Dellas, S
AU - Nitzsche, Eu
AU - Herrmann, R
AU - Maecke, Hr
PY - 1998
DA - 1998/02/01
PB - Elsevier
SP - 417-418
IS - 9100
VL - 351
PMID - 9482300
SN - 0140-6736
SN - 1474-547X
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{1998_Otte,
author = {Andreas Otte and J Mueller-Brand and S Dellas and Eu Nitzsche and R Herrmann and Hr Maecke},
title = {Yttrium-90-labelled somatostatin-analogue for cancer treatment},
journal = {The Lancet},
year = {1998},
volume = {351},
publisher = {Elsevier},
month = {feb},
url = {https://doi.org/10.1016/S0140-6736(05)78355-0},
number = {9100},
pages = {417--418},
doi = {10.1016/S0140-6736(05)78355-0}
}
MLA
Cite this
MLA Copy
Otte, A., et al. “Yttrium-90-labelled somatostatin-analogue for cancer treatment.” The Lancet, vol. 351, no. 9100, Feb. 1998, pp. 417-418. https://doi.org/10.1016/S0140-6736(05)78355-0.